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Abstract
Diffusion-weighted magnetic resonance imaging (DW-MRI) appears to hold promise as a non-invasive imaging
modality in the detection of early microstructural and functional changes of different organs. DW-MRI is an imaging
technique with a high sensitivity for the detection of a large variety of diseases in the urogenital tract. In kidneys, DW-
MRI has shown promise for the characterization of solid lesions. Also in focal T1 hyperintense lesions DW-MRI was
able to differentiate hemorrhagic cysts from tumours according to the lower apparent diffusion coefficient (ADC)
values reported for renal cell carcinomas. Promising results were also published for the detection of prostate
cancer. DW-MRI applied in addition to conventional T2-weighted imaging has been found to improve tumour
detection. On a 3 T magnetic resonance unit ADC values were reported to be lower for tumours compared with
the normal-appearing peripheral zone. The combined approach of T2-weighted imaging and DW-MRI also showed
promising results for the detection of recurrent tumour in patients after radiation therapy. DW-MRI may improve the
performance of conventional T2-weighted and contrast-enhanced MRI in the preoperative work-up of bladder cancer,
as it may help in distinguishing superficial from muscle invasive bladder cancer, which is critical for patient man-
agement. Another challenging application of DW-MRI in the urogenital tract is the detection of pelvic lymph node
metastases. As the ADC is generally reduced in malignant tumours and increased under inflammatory conditions,
reduced ADC values were expected in patients with lymph node metastases.
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Introduction
Conventional magnetic resonance imaging (MRI) and
computerized tomography (CT) are excellent techniques
for imaging the urogenital tract. Kidney tumours includ-
ing transitional cell carcinomas (TCCs) are routinely
staged with CT or in special cases with MRI. Local stag-
ing of prostate tumours can be performed only with
MRI, but CT is used in the search for distant metastases.
These techniques, however, only provide morphological
information on tumours; they lack information related to
tumour micro-architecture and biology.
Diffusion-weighted magnetic resonance imaging (DW-
MRI) measures microscopic mobility of water molecules
in the tissues. This mobility, which is classically called
Brownian motion, is caused by thermal motion and is
highly influenced by the cellular environment of water.
Thus, findings on DW-MRI can reflect biologic abnorm-
alities of the underlying tissues. The first clinical applica-
tions of DW-MRI were reported in the brain in the
1990s[1]. In the meantime DW-MRI is state-of-the-art
for the diagnosis of an acute stroke, as microstructural
changes observed on DW-MRI precede morphological
changes on conventional MRI or CT[2,3].
In the past, the use of DW-MRI for imaging the
abdomen was limited by a number of technical
challenges, mainly related to physiological motion
artefacts (bowel, cardiac and respiratory motion) and
the heterogeneous composition of the organs. However,
the latest technological developments have improved
the quality of DW-MRI sequences for the abdomen[4]
and there is now a broad spectrum of abdominal
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applications, including functional assessment of different
organs (e.g. the kidneys), tissue characterization, as well
as prediction and monitoring of treatment response in
tumours[5].
The present review outlines the basic principles of DW-
MRI and its applications in the urogenital tract (kidney,
bladder, prostate) are discussed with the main focus on
oncology including pelvic lymph node metastases.
Basics of DW-MRI
The most commonly used DW-MRI sequence is based on
the use of 2 equal-sized gradients, separated by a 180
radiofrequency (RF) pulse. The effect of these 2 gradi-
ents on water molecules is different according to their
movement. In stationary water molecules that have
not moved substantially between the first and second
gradient, the extra rotation induced by the second gradi-
ent will be identical to the first one and all of them will be
in phase at the end of the second gradient, generating
virtually a high signal. In contrast, in non-stationary water
molecules that have moved between the first and second
gradient, the second extra rotation will no longer be
identical to the first, and the molecule will be out of
phase, generating a lower signal than an in-phase config-
uration. The signal loss after the second gradient is also
dependent on the strength of the gradient (G) applied.
The amount of diffusion sensitizing applied is usually
indicated by the b value, which is given by b¼ 2
G2 2 (/3), where  is the gyromagnetic ratio,
G the strength of the gradient used,  is the duration of
the gradient and  is the time between the 2 gradients.
This signal loss as a function of the b value (or
diffusion weighting) usually shows an exponential
behaviour, which is generally displayed in a logarithmic
scale. By applying the following formula (Si¼ S0 
exp(biADC), where Si is the signal intensity mea-
sured using a b value bi and S0 is the signal intensity
for b¼ 0 s/mm2. It is then possible to calculate the appar-
ent diffusion coefficient (ADC) of water molecules[5],
which is usually displayed in pixel-by-pixel maps (ADC
maps) in a grey scale (higher and lower ADC values in
colour shades of light and dark grey, respectively).
All moving molecules in a tissue volume induce a
signal loss. This means that not only the diffusion of
water molecules in the extracellular extravascular space
but also cellular diffusion as well as intravascular per-
fusion contribute to the calculation of the ADC
value[2,4,6,7]. However, the effect of the movement of
water molecules on the ADC value is inversely related
to their speed at the moment of the MR examination.
Using low b values (typically up to 100150 s/mm2), the
fastest moving spins have the strongest effect. The origin
of these fast spins can most likely be attributed to micro-
perfusion and microcirculation effects and this phenom-
enon, also known as the intravoxel incoherent motion,
has been used to assess tissue perfusion[2,4,6,7]. Using
higher b values, the fastest moving spins have already
lost their signal; therefore, the effect of the slower move-
ments such as the Brownian displacement of extra- and
intracellular molecules and trans-membranous transport
can be assessed[8]. Whenever the micro-architecture of
a tissue is changed, either with respect to the blood
vessel density, to the addition and/or removal of struc-
tural inhibitors, or, most importantly, to the different
ratio of extracellular extravascular space over the intra-
cellular space, this can be detected using DW-MRI,
provided an optimal choice of b values is selected. For
example, a reduced ADC has been observed in most
types of malignant tumours as a result of the decrease
in extracellular extravascular space[8].
The selection of an appropriate imaging sequence is
essential for DW-MRI. In theory, any imaging sequence
can be adapted with bipolar gradients to allow the assess-
ment of water molecule diffusion. However, the fastest
and most often used sequence is a single-shot echo-planar
imaging (EPI) sequence, which is a gradient echo-based
technique and therefore has inherent problems with sus-
ceptibility, especially when many airtissue boundaries
are present. Also, movement artefacts tend to have a
stronger effect in gradient echo acquisitions. As both
factors are more pronounced in abdominal applications,
some researchers tend to use alternative acquisition
schemes such as single-shot turbo-spin-echo, steady-state
free precession, multi-shot EPI and line scan diffusion-
weighted imaging.
Technical requirements
Different sequences have been described for DW-MRI
of the urogenital tract.
Breath-hold sequences are fast (1520 s) and mini-
mally affected from pulsatility and motion artefacts, but
are limited in coverage, have a low signal-to-noise ratio
(SNR) (as they are performed with few averages) and
only allow application of a few b values.
Free breathing or respiratory triggered sequences
are now increasingly performed in the urogenital tract.
They allow for full region coverage and motion or pulsa-
tility artefacts are cancelled out with the use of multiple
averages, which also increase the SNR. The time of acqui-
sition for such sequences, however, is longer (45min)
than that required for breath-hold sequences. Both the
above-mentioned DW-MRI sequences are usually
acquired before contrast medium administration. Ima-
ging of the kidney is often performed in the coronal
plane, whereas imaging of the pelvis should be performed
in the transverse plane.
The choice of b values depends on the clinical indica-
tion. Only higher b values enable an estimate of true
diffusion of water molecules; whereas a combination of
high and low b values cannot separate the contribution
of perfusion and diffusion in tissues, generating higher
ADC values.
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The number of b values included in a sequence has also
to be decided according to the purpose of the study. The
higher the number of b values used, the more precise is
the ADC fit; on the other hand, the time of acquisition
increases according to the number of b values applied.
Therefore, multiple b values are required for bi-exponen-
tial fitting of the signal intensity curve, in order to sepa-
rate the contribution of perfusion from that of diffusion
in the calculation of ADC; in contrast, in the clinical
routine an acceptable ADC fit can usually be obtained
with 34 b values[9]. Typical parameters for a free breath-
ing axial EPI sequence adapted for imaging of the uro-
genital tract with a 1.5 T scanner include slice thickness
56mm with no intersection gap, field of view (FOV)
360400mm, matrix 104112/256, number of slices
4046, repetition time from 5000 to 7000ms, a echo
time as low as possible (6568ms), at least 3 b values
(e.g. 0, 500, 1000 s/mm2), parallel imaging (acceleration
factor 2), EPI factor 75112, bandwidth 1800Hz/pixel,
averages 45, acquisition time approximately 4min.
The administration of an anti-peristaltic agent such as
glucagon or hyoscine-N-butyl bromide helps to minimise
bowel motion and consequent susceptibility artefacts in
the pelvis; it is therefore recommended for DW-MRI of
the pelvis.
Magnetic susceptibility artefacts from hip prostheses
usually impair the quality of EPI-based DW-MRI
sequences, thus limiting its application in these patients.
Image analysis
The qualitative analysis of DW-MR images can be per-
formed by visual assessment. Tissues present a different
attenuation with increasing b values, which is related
to tissue cellularity, to the integrity of cell membranes
and to the tortuosity of the extracellular space[5,10].
Generally, at higher b values (e.g.4800 s/mm2), cellular
tissue (e.g. tumour tissue) shows less signal attenuation
(being hyperintense) than free fluid or necrotic/cystic
components of a tumour (being hypointense). However,
the interpretation of DW-MR images alone may have
limitations. For example, due to the T2 shine-through
effect, some normal tissues (e.g. the peripheral zone
(PZ) of the prostate) show high signal intensity even in
the higher b value DW-MR images. This occurs because
the signal intensity on the high b value DW-MR images
depends not only on the diffusion of water molecules but
also on the intrinsic tissue T2-relaxation time; a DW-MRI
EPI sequence is an adaptation from a T2-weighted spin-
echo sequence.
The easiest method to avoid misinterpretation because
of the T2 shine-through effect is to compare the high
b value DW-MR image with the corresponding ADC
map[10]. A tissue with a significant T2 shine-through
effect typically shows high signal intensity on the high
b value image, but returns a high ADC value, displayed in
colour shades of light grey on the corresponding ADC
maps (Fig. 1). Such a combined interpretation of DW-
MR images and ADC maps is therefore strongly advo-
cated for the urogenital tract, leading to a new radiologi-
cal interpretation of lesions. High signal intensity on the
high b value DW-MR images and colour shades of dark
grey on ADC maps indicate a cellular tissue, including
malignancy within the differential diagnosis (Fig. 2);
however, abscesses might also be cellular, with similar
appearance. When a lesion shows low signal intensity
in low b value images and colour shades of light grey
on ADC maps, it is mostly related to cystic or necrotic
components (Fig. 2). When a lesion shows low signal
intensity on high b value DW-MR images and colour
shades of dark grey on the ADC maps in grey scale,
some conditions could be considered, including sup-
pressed macroscopic fatty tissue, as well as susceptibility
artefacts (e.g. iron deposition) (Fig. 3).
The quantitative analysis of DW-MR images can be
performed by calculating the ADC values of tissues. A
region of interest (ROI) is manually drawn along tumour
margins, in each section where it is present. The ROI is
generally drawn on DW-MR images and then copied on
ADC maps, as tumour margins can be difficult to identify
on ADC maps. In renal lesions, which might show both
solid and necrotic/cystic components, it might be more
precise to draw different ROIs on the 2 different compo-
nents. The simplest and most frequently used method to
quantify the tumour ADC is by using summary statistics;
the mean or median ADC of the ROI can be easily
obtained and reported. However, the value obtained
does not reflect the distribution of the ADC values
within the ROI, thus providing a poor assessment of
tumour heterogeneity. The ADC values can also be ana-
lysed on a voxel-by-voxel basis, which allows the assess-
ment of the individual voxel values within an ROI. The
distribution of the ADC values within the ROI can be
displayed by histograms, which better reflect tumour
heterogeneity.
DW-MRI in different urogenital organs
Kidney
CT and MRI easily identify a renal neoplasm and usually
allow the diagnosis of a neoplastic process when contrast
enhancement is present. However, the difference between
complicated cysts and cystic renal cell carcinoma (RCC)
or between an oncocytoma and an RCC can be challen-
ging. In these cases, additional information might be
helpful for further characterization of unclear cystic or
solid lesions.
As a general rule, lower ADC values are expected in
solid lesions, reflecting impeded diffusion of water
molecules as a result of cellular density, compared with
those in cystic lesions. This has been confirmed by sev-
eral studies, which demonstrated a higher ADC in simple
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cysts than in normal parenchyma and in solid
lesions[11,12].
Using b values of 0, 500, and 1000 s/mm2, Zhang
et al.[13] demonstrated significantly lower ADC values
in the cystic/necrotic portions of a neoplasm compared
with simple cysts: 2.21 0.63 versus 3.26 0.61
(P50.05). The only study that compared the ADC
values of Bosniak cysts showed an ADC of 1.83 0.85
for complicated cysts (category IIIIV from Bosniak); an
ADC of 2.78 0.45 was observed for category I[14].
These encouraging results, however, need to be further
assessed in larger prospective studies.
Another diagnostic challenge for conventional cross-
sectional imaging is the differentiation between an onco-
cytoma and a solid RCC. Promising results have been
reported in a recent study, which demonstrated that renal
oncocytomas had a significantly higher (P¼ 0.0097)
ADC value compared with that of solid RCCs (mean
ADC values for b values of 0, 400, and 800 s/mm2
were 1.91 103 0.97 s/mm2 versus 1.54 103 
0.69 s/mm2, respectively)[14].
The potential of DW-MRI in the characterization of
focal renal lesions is of utmost importance in patients
with renal insufficiency, in view of the recently reported
concerns regarding the risk of development of nephro-
genic systemic fibrosis (NSF)[1518]. In a recent study
including 109 renal lesions (81 benign lesions and 28
RCCs), contrast-enhanced MRI performed better than
DW-MRI for the diagnosis of RCCs, but the authors
concluded that DW-MRI alone is currently a reasonable
alternative to contrast-enhanced MR or CT imaging for
the diagnosis of malignant renal neoplasms in patients
with renal insufficiency and/or are at risk for NSF[14] or
contrast materialinduced nephropathy[19]. In a recently
published study, the performance of DW-MRI was equiv-
alent to that of enhancement ratio in the characterization
Figure 1 MRI (at 1.5 T) of a 66-year-old male patient with a normal prostate. (A) Axial T2-weighted image shows high
signal intensity in the PZ of the prostate (arrows). (B) DW-MR image at a b value of 900 s/mm2 shows high signal
intensity in the PZ of the prostate, as a result of the T2 shine-through effect (arrows). (C) The PZ of the prostate returns
a high ADC value, represented by colour shades of light grey (arrows).
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of nonfat-containing T1 hyperintense renal lesions;
both methods had lower sensitivity than image subtrac-
tion, however without reaching significance[20]. The
results of this study further confirm the role of DW-
MRI as a valid alternative to contrast-enhanced imaging
by MR or CT, even in the above-mentioned clinical set-
ting, which is traditionally challenging for any imaging
modality.
Bladder
The most common type of bladder cancer is TCC. At the
time of diagnosis, more than 70% of bladder cancers are
superficial (stage T1 or lower), confined to the sub-
epithelial connective tissue[2123]; the remaining bladder
cancers are muscle invasive (stage T2) or extend
beyond the bladder (stage T3 or T4). Distinguishing
Figure 2 MRI (at 1.5 T) of a 79-year-old patient with an RCC in the left kidney (arrows). (A) Axial T2-weighted MR
image shows intermediate signal intensity of the RCC, which is comparable with that of normal parenchyma, and high
signal intensity for the multiple bilateral simple cysts (asterisk). (B) DW-MR image at a b value of 900 s/mm2 shows
high signal intensity of the RCC (arrows) and low signal intensity of the simple cysts (asterisk). (C) In the ADC map the
RCC is clearly visualized as an area of impeded diffusion (arrows), represented by colour shades of dark grey, in contrast
with the normal parenchyma of the left kidney and with the simple cysts (asterisk), which return colour shades of
intermediate and light grey, respectively.
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Figure 3 Qualitative analysis of the common patterns in DW-MRI, using high b value images and corresponding ADC
maps in grey scale (colour shades of light grey correspond to higher ADC values, whereas colour shades of dark grey
correspond to lower ADC values). Boxes in white indicate high signal intensity on high b value images and high ADC
values. Boxes in black indicate low signal intensity on high b value images and low ADC values.
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superficial from muscle invasive bladder cancer is critical
for patient management, because the treatment options
differ considerably. Superficial tumours are treated
with bladder sparing treatments, including transurethral
resection (TUR) with or without adjuvant intravesical
chemotherapy or photodynamic therapy[24]. A radical
cystectomy with lymphadenectomy, radiation therapy,
chemotherapy, or a combination is required for muscle
invasive bladder cancers[25]. Cystoscopy and TUR can
underestimate the local extent of the disease in the blad-
der[26]. Therefore, preoperative imaging able to precisely
differentiate between the 2 categories of bladder cancer
would have a great clinical impact.
Conventional MRI can visualize bladder tumours,
which appear slightly hyperintense relative to muscle
on T2-weighted sequences and isointense relative to
muscle on T1-weighted sequences[23]. T2a and T2b
tumours can occasionally be differentiated when on a
T2-weighted sequence the hypointense band (corre-
sponding to the muscle) is preserved, corresponding to
T2a tumours[23]. Macroscopic extravesical extension
(T3b) of the tumour can be seen on conventional
MRI, as a result of the presence of an irregular, ill-defined
outer bladder wall and soft-tissue nodules or fat stranding
in the surrounding perivesical fat[27]. However, conven-
tional MRI techniques cannot resolve the various bladder
wall layers accurately, thereby seriously limiting the accu-
racy of T staging, particularly in distinguishing among
muscle invasive (stage T2 or higher) and superficial
(stage T1 or lower) tumours.
Some authors observed that DW-MRI is superior to
T2-weighted MRI in staging of organ-confined tumours
(T2)[28] and may have high specificity (93%) for the
detection of invasive urinary bladder tumours[29]. The
additional value of DW-MRI for differentiating stage
Tis to T1 tumours from T2 to T4 tumours has been
investigated. In a recent study DW-MRI had increased
accuracy from 88% up to 98% when performed in addi-
tion to T2-weighted and contrast-enhanced imaging,
and from 79% up to 96% when performed in addition
to T2-weighted imaging alone[30]. Furthermore, the excel-
lent specificity for muscle invasion (100%) that has been
observed when DW-MRI is performed in combination
with T2-weighted imaging (with or without the addition
of contrast enhancement) suggests that preoperative ima-
ging may be able to differentiate between the 2 categories
of bladder cancer, which in selected patients may have a
clinical impact[30] (Fig. 4).
The prognosis of bladder tumours correlates inversely
with the histological grading. The ADC may in part pre-
dict the histological grade of a bladder cancer, as
observed in a recent study[30], which demonstrated that
the mean ADCs of G1, G2, and G3 tumours were
(1.29 0.21) 103 mm2/s, (1.13 0.24) 103
mm2/s and (0.81 0.11) 103 mm2/s, respectively,
with significantly lower ADC values for G3 tumours
compared with G1 (P50.01) and to G2 (P50.01)
tumours. In addition, DW-MRI in patients with bladder
cancer may detect bone metastases not diagnosed on
scintigraphy.
Prostate
When a prostate cancer reaches the size of so-called sig-
nificant disease (40.5mL), corresponding to a diameter
of 10mm, it is expected to produce 1.75 ng/mL of pros-
tate-specific antigen (PSA), since it is known that 1 g of
prostate cancer produces 3.5 ng/mL of PSA. However,
benign prostatic hyperplasia (BPH) as well as normal
prostatic tissue contributes to the total PSA, producing
0.3 ng/mL and 0.1 ng/mL of PSA per gram, respectively.
Therefore it is difficult to reliably predict prostate cancer
based on PSA level alone[31]. In a study from Thompson
et al.[32], 15.2% of men with a PSA level 4.0 ng/mL had
prostate cancer. Another study demonstrated prostate
cancer was detected in only 32% of those with a PSA
Figure 4 MRI (at 3 T) of a 69-year-old female patient
with a pT3 TCC of the bladder. (A) On the DW-MR image
at a b value of 1000 s/mm2 the tumour is seen as thicken-
ing of the anterior bladder wall with high signal intensity
and with irregular outer margins extending into the sur-
rounding fat tissue (arrows). (B) On the corresponding
ADC map the tumour is visualized as thickening of the
bladder wall with impeded diffusion, represented by colour
shades of dark grey (arrows).
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level between 4 and 10 ng/mL and in 41% of men with a
PSA level between 10.1 and 20 ng/mL[33].
Thus, even a PSA level510 ng/ml does not discrimi-
nate between prostate cancer and other prostate pathol-
ogies, such as, for example, prostatitis or BPH. The
diagnosis of prostate cancer is still based mostly on
the results of ultrasonography (US)-guided transrectal
biopsy, performed with multiple random samples, as
the low accuracy of US for prostate cancer detection
and localization often does not allow a targeted biopsy.
Advances in imaging are therefore of utmost importance
for the diagnosis of prostate cancer and for its
localization.
Because of the intrinsic low contrast resolution, CT is
not adequate for the assessment of organ-confined pros-
tate cancers. MRI using T2-weighted imaging has been
used for the work-up of prostate cancer, but is limited
because of unsatisfactory sensitivity and specificity for
prostate cancer detection and localization, especially
when the cancer is located in the transitional and central
zones, because cancer and normal tissues both have low
signal intensity on T2-weighted images. Furthermore,
differentiation between tumour and prostatitis is often
not possible.
Various other MR techniques have been applied for
prostate cancer imaging. Dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) is based on
the concept that tumours present different vascularity
as a result of the angiogenic process compared with back-
ground parenchyma. DCE-MRI has been used for
tumour localization[34], for the evaluation of tumour vas-
cularity[35], as well as for the discrimination of prostate
cancer in the PZ from normal PZ tissue, and stromal and
glandular BPH[36]. Some authors have observed better
performances of DCE-MRI compared with T2-weighted
imaging in tumour detection at 1.5 T[35] and at 3 T[37,38].
Proton (1H) MR spectroscopic imaging (MRSI) has
also been used for prostate cancer work-up. The detection
of prostate cancer has been based primarily on the
identification of an increased choline-to-citrate ratio, or,
for practical purposes, the choline plus the creatine
(ChoþCr)/citrate ratio. The use of combined MRI/
MRSI is generally considered to improve the specificity
of prostate cancer detection and it may also be useful
for risk stratification of prostate cancers[38,39].
However, in a recent multicentric study the accuracy of
combined imaging including endorectal MRI and MRSI
at 1.5 T for the sextant localization of prostate cancer
in the PZ was found to be comparable with that of
T2-weighted MRI alone[40]. Such a modest performance
of MRSI could also be explained by the difficulty of the
technique, requiring experience in data acquisition and
interpretation.
Although DCE-MRI and 1H MR spectroscopy have
shown promise both for tumour detection and character-
ization, neither method provides image resolution suffi-
cient for practical tumour localization[4143].
DW-MRI is feasible on the prostate and the calculation
of the ADC values is relatively straightforward. In
the prostate tissue, the predominant contribution of the
extracellular component is from tubular structures and
their fluid content, whereas the intracellular component
is determined by the epithelial and stromal cells.
In most cases, the PZ can be easily discriminated from
the central gland (CG), because it displays relatively
higher ADC values compared with the PZ[4447]. The
CG consists of more compact smooth muscle cells and
sparser glandular elements than the PZ, leading to a
lower extracellular-to-intracellular fluid ratio and to
lower ADC values. Prostate carcinoma is histologically
characterized by a higher cellular density than normal
prostate tissue, with replacement of the normal glandular
tissue; thus, it is expected to show a more impeded
diffusion of water molecules, compared with normal pro-
static gland[48,49].
Several studies have demonstrated significantly lower
ADC values in prostate carcinoma compared with benign
prostatic tissue[5053], suggesting clinical utility in pros-
tate cancer detection. In particular, the addition of DW-
MRI to T2-weighted MRI has been shown to improve the
detection of prostatic carcinoma in the PZ[54], as a result
of the contrast between the low ADC values of the pros-
tate carcinoma and the relatively high ADC values of the
PZ, in which tumours occur in 70% of cases[55] (Fig. 5).
The addition of DW-MRI to T2-weighted MRI also
provides a definitely higher spatial resolution than
MRSI and DCE-MRI. A close correlation between DW-
MRI and histology has been demonstrated in a study by
Xu et al.[56] for the visualization of prostate cancer.
Similar results were reported in a study showing that
the addition of DW-MRI to T2-weighted imaging can
significantly improve the accuracy of prostate PZ
tumour volume measurements[57]. The results of the
above-mentioned studies showed the ability of DW-MRI
to image prostate cancers when they are larger than 0.1
cm3, suggesting its potential role for prostate cancer
localization, when it is located in the PZ.
However, detection and localization of prostate carci-
noma in the CG remain challenging, as there is an over-
lap in ADC values between tumour and BPH. In these
cases, diffusion tensor imaging (DTI), which allows for
the evaluation of tissue anisotropy, is showing promise.
Fractional anisotropy (FA) is determined along the
axis of the tubular structures of normal prostate tissue.
High FA is generally observed in stromal BPH, thus
avoiding false-positive identification of a prostate carci-
noma in the CG; FA is reduced[50,58] in prostate carci-
noma, as a result of the destruction of tubular structures.
DTI has therefore the potential to provide information on
prostate microstructure at a micrometre scale, but further
clinical studies are needed to identify its role in prostate
cancer imaging.
Preliminary studies have been published recently, eval-
uating the prognostic value of ADC in prostate tumours.
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Both ADC values calculated with b values from 0 to 100
and with b values from 100 to 800 s/mm2 were found to
be significantly lower in patients with higher risk com-
pared with those with low risk localized prostate
cancer[59]. In patients with untreated localized prostate
cancer on active surveillance, low tumour ADC values
were associated with adverse histology on repeat biopsy
and shorter time to deferred radical treatment[60].
There is a short experience in treatment monitoring of
prostate tumours by DW-MRI. To the best of our knowl-
edge, there is only one study on humans that used DW-
MRI for monitoring carbon-ion radiotherapy, which
demonstrated a significant increase in tumour ADC
values after therapy (39 months after treatment); no
changes in the non-cancerous inner gland (IG) and in
the PZ[61] were observed. DW-MRI has also been applied
for early monitoring of thermal therapy in canine normal
prostate. In the treated area authors observed a decrease
in ADC values a few days after thermal therapy and an
increase over time as the treated area recovered and
regenerated[62]. These studies showed that DW-MRI
might also have a role for monitoring non-surgical thera-
pies in prostate cancer. However, further studies are
required to identify a role for DW-MRI with respect to
predicting clinical outcomes and treatment monitoring.
To the best of our knowledge, there is only one study
that investigated the role of DW-MRI in recurrent pros-
tate cancer[63]. This study showed that DW-MRI, when
added to T2-weighted imaging, improved the ability
to discriminate between recurrent disease and post-
therapeutic changes in patients who have received radio-
therapy treatment. These encouraging results suggest a
Figure 5 MRI (at 3 T) of a 69-year-old patient with a prostate carcinoma in the PZ on the right side (arrow). (A) On
the axial T2-weighted MR image the tumour is visualized as an area of low signal intensity (arrow). (B) On the DW-MR
image at a b value of 1000 s/mm2 the tumour is not clearly visualized because of the T2 shine-through effect in the PZ of
the prostate. (C) On the ADC map the tumour is clearly visualized as an area of impeded diffusion, represented by colour
shades of dark grey, in contrast with the normal PZ of the prostate, which returns colour shades of light grey.
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validation of the role of DW-MRI for recurrent prostate
carcinoma on a larger scale, as an earlier diagnosis and a
more accurate intraprostatic mapping of the recurred
prostate cancer after radiation therapy can provide
better selection of the appropriate second-line treatment.
Lymph nodes
Lymph node staging in patients with bladder or prostate
tumours is based on size criteria only when performing
conventional cross-sectional imaging, such as CT and
MR. This may not be adequate for staging such tumours,
because micrometastases are demonstrated in about
25% of patients with preoperatively negative normal-
sized lymph nodes on imaging studies[64,65]. In addition,
it has been demonstrated that the incidence of positive
lymph nodes is higher in patients with a Gleason score
7 (25%) compared with those with a Gleason score
56 (3%)[66], and that the survival is significantly better
in the absence of lymph node involvement in patients
with bladder cancer. Thus, there is an urgent need for
an improvement in the diagnosis of malignant lymph
nodes by preoperative imaging.
DW-MRI may have a role in the assessment of malig-
nant lymph nodes from urogenital tumours, because
malignant nodes are in theory expected to show impeded
diffusion, resulting in low ADC values, as most primary
malignant tumours show impeded diffusion caused by
high cellularity (Fig. 6). There is one study including
29 patients that investigated the potential contribution
of ADC values in the differentiation between benign
and malignant lymph nodes in patients with prostate
cancer, showing significant differences in the mean
ADC for b values of 50, 300, and 600 s/mm2 between
malignant (1.07 0.23 103mm2/s) and benign
(1.54 0.25 103 mm2/s) lymph nodes[67]. However,
definitive data are not yet available and the potential of
DW-MRI for lymph node assessment in normal-sized
nodes is still being investigated.
Future challenges
The lack of standardization in imaging technique and
analysis is one of the most important shortcomings of
DW-MRI, which slightly hampers its use in clinical prac-
tice and limits comparison between studies. The use of
DW-MR sequences with different parameters, as well as
the use of different field strengths and MR scanners from
different manufacturers may raise variability in the qual-
itative and quantitative assessment of DW-MRI.
Therefore identical parameters of DW-MR sequences
are a prerequisite to perform longitudinal studies and
to compare results with those published in the litera-
ture[7,68]. Efforts have been conducted in the last few
years to standardize DW-MRI sequences and image ana-
lysis[69,70]; however, there is still a lack of official guide-
lines from the major scientific societies, which may
contribute to expand this knowledge to a wider commu-
nity, including newcomers and clinicians.
First goals would be standardization of image acquisi-
tion and sequences across multiple scanner platforms in
multiple institutions, accounting for equipment variability
as well as for the differences in imaging practice across
different sites. Then, reading/analysis bias must be con-
trolled in the qualitative and quantitative analysis of DW-
MRI. The achievement of these goals would permit multi-
site clinical trials, which are required for a definitive val-
idation of such a technique in the assessment of urogen-
ital tract tumours.
Other goals would be to explore the potential of DW-
MRI for tumours of the urogenital tract as a biomarker
in clinical practice, able to influence patient manage-
ment, or in drug development, providing insights into
the efficacy and/or toxicity of a compound. For example,
anti-angiogenic therapy, including tyrosine kinase
inhibitors (sunitinib and sorafenib), bevacizumab with
interferon alpha, temsirolimus, and everolimus, is increas-
ingly used for metastatic RCC[71]. As these new agents
Figure 6 MRI (at 3 T) of a 50-year-old patient with 2
lymph node metastases from prostate carcinoma in the
right external iliac chain. (A) On the DW-MR image at
a b value of 1000 s/mm2 the lymph node metastases show
high signal intensity (arrows). (B) On the corresponding
ADC map the lymph node metastases reveal impeded dif-
fusion, represented by colour shades of dark grey.
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do not lead to an immediate size reduction of the tumour,
newer imaging techniques providing microstructural
information are warranted.
DW-MRI has been shown to be able to demonstrate
changes prior to alterations in tumour size after drug
treatment and has thus been proposed as a potential
biomarker of early drug activity. On the other hand,
there are now multiple early-phase clinical trials of anti-
angiogenic agents in prostate cancer[72]. A biomarker for
estimating the optimal dose and scheduling is therefore
required; there are preliminary experiences reporting the
potential of DW-MRI to provide such an evaluation, pro-
viding different ADC values at different dose levels and
days of therapy[73]. However, the validation of DW-MRI
as a biomarker in drug development is linked to its inte-
gration into a platform of multifunctional MR imaging.
Improvements in lymph node imaging are necessary.
Further efforts are needed to explore the potential of
DW-MRI (eventually in combination with ultrasmall
superparamagnetic iron oxide-enhanced MRI) to detect
lymph node metastases even in normal-sized lymph
nodes[74] and to differentiate between enlarged reactive
nodes and metastases in RCC, for example.
Conclusion
Although MR and CT are excellent imaging modalities in
the diagnostic work-up of several urogenital tumours,
DW-MRI is showing promising results as a non-invasive
and sensitive technique to provide information one step
beyond morphology. Therefore, DW-MRI merits further
studies to validate its potential for application in tumours
of the urogenital tract in larger scale studies.
Acknowledgement
This work was supported by research grant no. 320000
113512 of the Swiss National Science Foundation for
Research and Carigest SA, Geneva.
References
[1] Moseley ME, Cohen Y, Mintorovitch J, et al. Early detection of
regional cerebral ischemia in cats: comparison of diffusion- and
T2-weighted MRI and spectroscopy. Magn Reson Med 1990; 14:
33046. doi:10.1002/mrm.1910140218. PMid:2345513.
[2] Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR
imaging of the brain. Radiology 2000; 217: 33145.
[3] Johnston KC, Wagner DP, Wang XQ, et al. Validation of an
acute ischemic stroke model: does diffusion-weighted imaging
lesion volume offer a clinically significant improvement in pre-
diction of outcome? Stroke 2007; 38: 18205. doi:10.1161/
STROKEAHA.106.479154. PMid:17446421.
[4] Murtz P, Flacke S, Traber F, van den Brink JS, Gieseke J,
Schild HH. Abdomen: diffusion-weighted MR imaging with
pulse-triggered single-shot sequences. Radiology 2002; 224:
25864. doi:10.1148/radiol.2241011117. PMid:12091693.
[5] Thoeny HC, De Keyzer F. Extracranial applications of diffusion-
weighted magnetic resonance imaging. Eur Radiol 2007; 17:
138593. doi:10.1007/s00330-006-0547-0. PMid:17206421.
[6] Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J,
Laval-Jeantet M. Separation of diffusion and perfusion in intra-
voxel incoherent motion MR imaging. Radiology 1988; 168:
497505.
[7] Thoeny HC, De Keyzer F, Boesch C, Hermans R. Diffusion-
weighted imaging of the parotid gland: Influence of the choice
of b-values on the apparent diffusion coefficient value. J Magn
Reson Imaging 2004; 20: 78690. doi:10.1002/jmri.20196.
PMid:15503336.
[8] Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density
and necrotic fraction in human melanoma xenografts by diffusion
weighted magnetic resonance imaging. Magn Reson Med 2000;
43: 82836. doi:10.1002/1522-2594(200006)43:65828::AID-
MRM843.0.CO;2-P.
[9] Kim S, Naik M, Sigmund E, Taouli B. Diffusion-weighted MR
imaging of the kidneys and the urinary tract. Magn Reson
Imaging Clin N Am 2008; 16: 58596. doi:10.1016/
j.mric.2008.07.006. PMid:18926424.
[10] Koh DM, Collins DJ. Diffusion-weighted MRI in the body: appli-
cations and challenges in oncology. AJR Am J Roentgenol 2007;
188: 162235. doi:10.2214/AJR.06.1403. PMid:17515386.
[11] Squillaci E, Manenti G, Di Stefano F, Miano R, Strigari L,
Simonetti G. Diffusion-weighted MR imaging in the evaluation
of renal tumours. J Exp Clin Cancer Res 2004; 23: 3945.
[12] Cova M, Squillaci E, Stacul F, et al. Diffusion-weighted
MRI in the evaluation of renal lesions: preliminary results.
Br J Radiol 2004; 77: 8517. doi:10.1259/bjr/26525081. PMid:
15482997.
[13] Zhang J, Tehrani YM, Wang L, Ishill NM, Schwartz LH,
Hricak H. Renal masses: characterization with diffusion-weighted
MR imaginga preliminary experience. Radiology 2008; 247:
45864. doi:10.1148/radiol.2472070823. PMid:18430878.
[14] Taouli B, Thakur RK, Mannelli L, et al. Renal lesions: character-
ization with diffusion-weighted imaging versus contrast-enhanced
MR imaging. Radiology 2009; 251: 398407. doi:10.1148/
radiol.2512080880. PMid:19276322.
[15] Grobner T. Gadoliniuma specific trigger for the development
of nephrogenic fibrosing dermopathy and nephrogenic
systemic fibrosis? Nephrol Dial Transplant 2006; 21: 11048.
doi:10.1093/ndt/gfk062. PMid:16431890.
[16] Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic
systemic fibrosis: risk factors and incidence estimation.
Radiology 2007; 243: 14857. doi:10.1148/radiol.2431062144.
PMid:17267695.
[17] Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephro-
genic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:
2730. doi:10.1016/j.jaad.2006.10.048. PMid:17109993.
[18] Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced
nephrotoxicity: a consensus report. Contrast Media Safety
Committee, European Society of Urogenital Radiology (ESUR).
Eur Radiol 1999; 9: 160213. doi:10.1007/s003300050894.
PMid:10525875.
[19] Mehran R, Nikolsky E. Contrast-induced nephropathy: definition,
epidemiology, and patients at risk. Kidney Int 2006(Suppl):
S115.
[20] Kim S, Jain M, Harris AB, et al. T1 hyperintense renal lesions:
characterization with diffusion-weighted MR imaging versus con-
trast-enhanced MR imaging. Radiology 2009; 251: 796807.
doi:10.1148/radiol.2513080724. PMid:19380690.
[21] Bradford TJ, Montie JE, Hafez KS. The role of imaging in the
surveillance of urologic malignancies. Urol Clin North Am 2006;
33: 37796. doi:10.1016/j.ucl.2006.03.001. PMid:16829272.
[22] Kaufman DS. Challenges in the treatment of bladder cancer. Ann
Oncol 2006; 17(Suppl 5): v10612. doi:10.1093/annonc/mdj963.
PMid:16807436.
[23] Ng CS. Radiologic diagnosis and staging of renal and bladder
cancer. Semin Roentgenol 2006; 41: 12138. doi:10.1053/
j.ro.2006.02.005. PMid:16697891.
Tuesday 5 October 2010 S121
[24] Josephson D, Pasin E, Stein JP. Superficial bladder cancer: part
2. Management. Expert Rev Anticancer Ther 2007; 7: 56781.
doi:10.1586/14737140.7.4.567. PMid:17428176.
[25] Sherif A, Jonsson MN, Wiklund NP. Treatment of muscle-inva-
sive bladder cancer. Expert Rev Anticancer Ther 2007; 7:
127983. doi:10.1586/14737140.7.9.1279. PMid:17892428.
[26] Herr HW. The value of a second transurethral resection in eval-
uating patients with bladder tumors. J Urol 1999; 162: 746.
doi:10.1097/00005392-199907000-00018. PMid:10379743.
[27] Vikram R, Sandler CM, Ng CS. Imaging and staging of transi-
tional cell carcinoma: part 1, lower urinary tract. AJR Am
J Roentgenol 2009; 192: 14817. doi:10.2214/AJR.08.1318.
PMid:19457808.
[28] El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour
staging: comparison of diffusion- and T2-weighted MR imaging.
Eur Radiol 2009; 19: 157581. doi:10.1007/s00330-009-1340-7.
PMid:19247665.
[29] Watanabe H, Kanematsu M, Kondo H, et al. Preoperative T
staging of urinary bladder cancer: does diffusion-weighted MRI
have supplementary value? AJR Am J Roentgenol 2009; 192:
13616. doi:10.2214/AJR.08.1430. PMid:19380561.
[30] Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: dif-
fusion-weighted MR imagingaccuracy for diagnosing T stage
and estimating histologic grade. Radiology 2009; 251: 11221.
doi:10.1148/radiol.2511080873. PMid:19332849.
[31] Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate
cancer risk: results from the Prostate Cancer Prevention Trial. J
Natl Cancer Inst 2006; 98: 52934.
[32] Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of
prostate cancer among men with a prostate-specific antigen
level 5 or¼ 4.0 ng per milliliter. N Engl J Med 2004; 350:
223946. doi:10.1056/NEJMoa031918. PMid:15163773.
[33] Carlson GD, Calvanese CB, Partin AW. An algorithm combining
age, total prostate-specific antigen (PSA), and percent free PSA to
predict prostate cancer: results on 4298 cases. Urology 1998; 52:
45561. doi:10.1016/S0090-4295(98)00205-2.
[34] Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer
localization with dynamic contrast-enhanced MR imaging and
proton MR spectroscopic imaging. Radiology 2006; 241:
44958. doi:10.1148/radiol.2412051866. PMid:16966484.
[35] Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE.
Prostate cancer: evaluation of vascular characteristics with
dynamic contrast-enhanced T1-weighted MR imaginginitial
experience. Radiology 2004; 233: 70915. doi:10.1148/
radiol.2333032098. PMid:15498903.
[36] Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J.
Dynamic contrast-enhanced MRI in normal and abnormal pros-
tate tissues as defined by biopsy, MRI, and 3D MRSI. Magn
Reson Med 2005; 53: 24955. doi:10.1002/mrm.20374.
PMid:15678552.
[37] Kim CK, Park BK, Kim B. Localization of prostate cancer using
3T MRI: comparison of T2-weighted and dynamic contrast-
enhanced imaging. J Comput Assist Tomogr 2006; 30: 711.
doi:10.1097/01.rct.0000185384.27765.09. PMid:16365565.
[38] Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of mag-
netic resonance imaging and spectroscopy for predicting insignif-
icant prostate cancer: an initial analysis. BJU Int 2007; 99:
78693. doi:10.1111/j.1464-410X.2007.06689.x. PMid:
17223922.
[39] Coakley FV, Chen I, Qayyum A, et al. Validity of prostate-specific
antigen as a tumour marker in men with prostate cancer managed
by watchful-waiting: correlation with findings at serial endorectal
magnetic resonance imaging and spectroscopic imaging. BJU
Int 2007; 99: 415. doi:10.1111/j.1464-410X.2006.06515.x.
PMid:17227490.
[40] Weinreb JC, Blume JD, Coakley FV, et al. Prostate cancer:
sextant localization at MR imaging and MR spectroscopic ima-
ging before prostatectomy  results of ACRIN prospective
multi-institutional clinicopathologic study. Radiology 2009; 251:
12233. doi:10.1148/radiol.2511080409. PMid:19332850.
[41] Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance
imaging and spectroscopic imaging of prostate cancer. J Urol
2003; 170: S6975; discussion S7566. doi:10.1097/01.ju.
0000094958.23276.c4. PMid:14610414.
[42] Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast
enhanced MRI of prostate cancer: correlation with morphology
and tumour stage, histological grade and PSA. Clin Radiol 2000;
55: 99109. doi:10.1053/crad.1999.0327. PMid:10657154.
[43] Xu J, Does MD, Gore JC. Sensitivity of MR diffusion measure-
ments to variations in intracellular structure: effects of nuclear
size. Magn Reson Med 2009; 61: 82833. doi:10.1002/
mrm.21793. PMid:19205020.
[44] Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-
weighted imaging for the prediction of prostate cancer location
at 3T using a phased-array coil: preliminary results. Invest Radiol
2007; 42: 8427. doi:10.1097/RLI.0b013e3181461d21. PMid:
18007156.
[45] Kumar V, Jagannathan NR, Kumar R, et al. Apparent diffusion
coefficient of the prostate in men prior to biopsy: determination
of a cut-off value to predict malignancy of the peripheral zone.
NMR Biomed 2007; 20: 50511. doi:10.1002/nbm.1114.
PMid:17167820.
[46] Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient
values in peripheral and transition zones of the prostate: compar-
ison between normal and malignant prostatic tissues and correla-
tion with histologic grade. J Magn Reson Imaging 2008; 28:
7206. doi:10.1002/jmri.21503. PMid:18777532.
[47] Tamada T, Sone T, Toshimitsu S, et al. Age-related and zonal
anatomical changes of apparent diffusion coefficient values in
normal human prostatic tissues. J Magn Reson Imaging 2008;
27: 5526. doi:10.1002/jmri.21117. PMid:18219616.
[48] Anderson AW, Xie J, Pizzonia J, Bronen RA, Spencer DD,
Gore JC. Effects of cell volume fraction changes on apparent
diffusion in human cells. Magn Reson Imaging 2000; 18:
68995. doi:10.1016/S0730-725X(00)00147-8.
[49] Song SK, Qu Z, Garabedian EM, Gordon JI, Milbrandt J,
Ackerman JJ. Improved magnetic resonance imaging detection
of prostate cancer in a transgenic mouse model. Cancer Res
2002; 62: 15558.
[50] Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of
the prostate at 3.0 tesla. Invest Radiol 2006; 41: 1858. doi:
10.1097/01.rli.0000192418.30684.14. PMid:16428991.
[51] Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted ima-
ging in prostate cancer to differentiate malignant and benign
peripheral zone tissue. J Magn Reson Imaging 2004; 20:
65461. doi:10.1002/jmri.20159. PMid:15390142.
[52] Shimofusa R, Fujimoto H, Akamata H, et al. Diffusion-
weighted imaging of prostate cancer. J Comput Assist Tomogr
2005; 29: 14953. doi:10.1097/01.rct.0000156396.13522.f2.
PMid:15772529.
[53] Haider MA, van der Kwast TH, Tanguay J, et al. Combined
T2-weighted and diffusion-weighted MRI for localization of
prostate cancer. AJR Am J Roentgenol 2007; 189: 3238.
doi:10.2214/AJR.07.2211. PMid:17646457.
[54] Morgan VA, Kyriazi S, Ashley SE, DeSouza NM. Evaluation of
the potential of diffusion-weighted imaging in prostate cancer
detection. Acta Radiol 2007; 48: 695703. doi:10.1080/
02841850701349257. PMid:17611881.
[55] Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho KS.
Functional MR imaging of prostate cancer. Radiographics
2007; 27: 6375; discussion 7567. doi:10.1148/rg.271065078.
PMid:17234999.
[56] Xu J, Humphrey PA, Kibel AS, et al. Magnetic resonance diffu-
sion characteristics of histologically defined prostate cancer in
humans. Magn Reson Med 2009; 61: 84250. doi:10.1002/
mrm.21896. PMid:19215051.
S122 Focus on: Head and neck neoplasms
[57] Mazaheri Y, Hricak H, Fine SW, et al. Prostate tumor volume
measurement with combined T2-weighted imaging and diffusion-
weighted MR: correlation with pathologic tumor volume.
Radiology 2009; 252: 44957. doi:10.1148/radiol.2523081423.
PMid:19703883.
[58] Manenti G, Carlani M, Mancino S, et al. Diffusion tensor mag-
netic resonance imaging of prostate cancer. Invest Radiol 2007;
42: 4129. doi:10.1097/01.rli.0000264059.46444.bf. PMid:
17507813.
[59] deSouza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted
magnetic resonance imaging: a potential non-invasive marker
of tumour aggressiveness in localized prostate cancer.
Clin Radiol 2008; 63: 77482. doi:10.1016/j.crad.2008.02.001.
PMid:18555035.
[60] van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-
weighted magnetic resonance imaging in men with untreated loca-
lised prostate cancer on active surveillance. Eur Urol 2008; 56:
9818. doi:10.1016/j.eururo.2008.11.051. PMid:19095345.
[61] Takayama Y, Kishimoto R, Hanaoka S, et al. ADC value and
diffusion tensor imaging of prostate cancer: changes in carbon-
ion radiotherapy. J Magn Reson Imaging 2008; 27: 13315.
doi:10.1002/jmri.21388. PMid:18504751.
[62] Chen J, Daniel BL, Diederich CJ, et al. Monitoring prostate ther-
mal therapy with diffusion-weighted MRI. Magn Reson Med
2008; 59: 136572. doi:10.1002/mrm.21589. PMid:18506801.
[63] Kim CK, Park BK, Lee HM. Prediction of locally recurrent
prostate cancer after radiation therapy: incremental value of 3T
diffusion-weighted MRI. J Magn Reson Imaging 2009; 29: 3917.
doi:10.1002/jmri.21645. PMid:19161194.
[64] Fleischmann A, Thalmann GN, Markwalder R, Studer UE.
Extracapsular extension of pelvic lymph node metastases from
urothelial carcinoma of the bladder is an independent prognostic
factor. J Clin Oncol 2005; 23: 235865. doi:10.1200/JCO.
2005.03.084. PMid:15800327.
[65] Bader P, Burkhard FC, Markwalder R, Studer UE. Disease pro-
gression and survival of patients with positive lymph nodes after
radical prostatectomy. Is there a chance of cure? J Urol 2003;
169: 84954.
[66] Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A,
Studer UE. Is pelvic lymph node dissection necessary in patients
with a serum PSA510 ng/ml undergoing radical prostatectomy
for prostate cancer? Eur Urol 2006; 50: 2729. doi:10.1016/
j.eururo.2006.01.061. PMid:16632187.
[67] Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for
characterization of pelvic lymph nodes in patients with prostate
cancer by diffusion-weighted MR-imaging. Invest Radiol 2010; 45:
1523. doi:10.1097/RLI.0b013e3181bbdc2f. PMid:19996762.
[68] Dale BM, Braithwaite AC, Boll DT, Merkle EM. Field strength
and diffusion encoding technique affect the apparent diffusion
coefficient measurements in diffusion-weighted imaging of
the abdomen. Invest Radiol 2010; 45: 1048. doi:10.1097/
RLI.0b013e3181c8ceac. PMid:20027117.
[69] Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic
resonance imaging as a cancer biomarker: consensus and recom-
mendations. Neoplasia 2009; 11: 10225.
[70] Thoeny HC, Ross BD. Predicting and monitoring cancer treat-
ment response with diffusion-weighted MRI. J Magn Reson
Imaging 2010; 32: 216. doi:10.1002/jmri.22167. PMid:
20575076.
[71] Hutson TE, Figlin RA. Novel therapeutics for metastatic renal
cell carcinoma. Cancer 2009; 115: 23617. doi:10.1002/
cncr.24235. PMid:19402059.
[72] Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibitors in the
treatment of prostate cancer. Expert Opin Pharmacother 2010;
11: 23347. doi:10.1517/14656560903451716. PMid:20088745.
[73] Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the
functional diffusion map as an early biomarker of time-to-progres-
sion and overall survival in high-grade glioma. Proc Natl Acad Sci
U S A 2005; 102: 1675964. doi:10.1073/pnas.0508347102.
PMid:16267128.
[74] Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined
ultrasmall superparamagnetic particles of iron oxide-enhanced
and diffusion-weighted magnetic resonance imaging reliably
detect pelvic lymph node metastases in normal-sized nodes of
bladder and prostate cancer patients. Eur Urol 2009; 55:
7619. doi:10.1016/j.eururo.2008.12.034. PMid:19144456.
Tuesday 5 October 2010 S123
